Infliximab for acute exacerbations of ulcerative colitis

Review proposal consultation

Stakeholder matrix (PDF 253 KB)

Review proposal paper (PDF 328 KB)

Ulcerative colitis (acute exacerbations) - infliximab: review decision - June 2011 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 80 KB)

Ulcerative colitis (acute exacerbations) - infliximab: review proposal - April 2011 information

Appendix A: provisional matrix of stakeholders (PDF 84 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 111 KB)

NICE appraisal of infliximab for acute ulcerative colitis (PDF 35 KB)

Ulcerative colitis (acute exacerbations) - infliximab: final appraisal determination information

Ulcerative colitis (acute exacerbations) - infliximab: final appraisal determination document (PDF 122 KB)

Ulcerative colitis (acute exacerbations) - infliximab: table of comments on the ACD (PDF 71 KB)

Ulcerative colitis (acute exacerbations) - infliximab: FAD comments - Dr Sally Mitton (PDF 18 KB)

Ulcerative colitis (acute exacerbations) - infliximab: Consultee and commentator comments on the ACD

Ulcerative colitis (acute exacerbations) - infliximab: FAD comments - Department of Health (PDF 13 KB)

Ulcerative colitis (acute exacerbations) - infliximab: FAD comments - National Association for Colitis and Crohn's Disease (PDF 15 KB)

Ulcerative colitis (acute exacerbations) - infliximab: FAD comments - Royal College of Nurses (PDF 19 KB)

Ulcerative colitis (acute exacerbations) - infliximab: FAD comments - Royal College of Pathologists (PDF 30 KB)

Ulcerative colitis (acute exacerbations) - infliximab: FAD comments - Royal College of Physicians (PDF 47 KB)

Ulcerative colitis (acute exacerbations) - infliximab: FAD comments - Schering Plough (PDF 40 KB)

Ulcerative colitis (acute exacerbations) - infliximab: appraisal consultation

Ulcerative colitis (acute exacerbations) - infliximab: appraisal consultation document information

Ulcerative colitis (acute exacerbations) - infliximab: evaluation report

Evaluation report: pre-meeting briefing (PDF 143 KB)

Evaluation report: evidence review group report (PDF 400 KB)

Evaluation report: non-manufacturer submissions

Non-manufacturer submissions: Royal College of Nursing (PDF 53 KB)

Non-manufacturer submissions: Royal College of Pathologists (PDF 33 KB)

Non-manufacturer submissions: Royal College of Physicians (PDF 52 KB)

Non-manufacturer submissions: Medway PCT (PDF 22 KB)

Manufacturer submission: Schering Plough (PDF 1.28 MB)

Evaluation report: expert written personal statements

Expert written personal statements: Berliner (PDF 66 KB)

Expert written personal statements: Driscoll (PDF 50 KB)

Expert written personal statements: Rampton (PDF 16 KB)

Expert written personal statements: Rhodes (PDF 18 KB)

Ulcerative colitis (acute exacerbations) - infliximab: draft scope (PDF 37 KB)

Ulcerative colitis (acute exacerbations) - infliximab: final matrix (PDF 41 KB)

Ulcerative colitis (acute exacerbations) - infliximab: consultees and commentators information

Ulcerative colitis (acute exacerbations) - infliximab: draft matrix (PDF 35 KB)

Ulcerative colitis (acute exacerbations) - infliximab: draft scope (PDF 37 KB)